The protective effects in NASH conferred by liraglutide, a glucagon-like peptide-1 (GLP-1) analog, are mediated through the inhibition of the NLRP3 inflammasome and pyroptosis, and activation of mitophagy in hepatocytes. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.